Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer
NCT07164976
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
86
Enrollment
OTHER
Sponsor class
Conditions
Breast Cancer
Interventions
DRUG:
Ribociclib 400mg
DRUG:
Ribociclib 600mg
DRUG:
Ribociclib 600mg
Sponsor
Nagoya City University
Collaborators
[object Object]